Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
59 hedge funds and large institutions have $251M invested in Y-mAbs Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
31% more funds holding
Funds holding: 45 → 59 (+14)
13% more capital invested
Capital invested by funds: $222M → $251M (+$28.6M)
7.29% more ownership
Funds ownership: 24.8% → 32.09% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18M |
| 2 |
AG
Artal Group
Luxembourg
|
+$9.19M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.53M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.51M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$24.1M |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$125K |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$78.1K |
| 4 |
Barclays
London,
United Kingdom
|
-$72K |
| 5 |
FCM
Flinton Capital Management
Philadelphia,
Pennsylvania
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
51
Metropolitan Life Insurance Company (MetLife)
New York
| $36.3K | +$36.5K | +1,589 | New |
|
52
Canada Life
Winnipeg,
Manitoba, Canada
| $32K | +$31.8K | +1,383 | New |
|
|
MCIM
53
Meadow Creek Investment Management
Atlanta,
Georgia
| $27K | -$18.4K | -800 | -41% |
|
54
BNP Paribas Financial Markets
Paris,
France
| $19.6K | -$13.6K | -592 | -41% |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| $17K | +$12.1K | +525 | +244% |
|
|
CSS
56
Cubist Systematic Strategies
Stamford,
Connecticut
| $12K | +$11.9K | +520 | New |
|
|
PCM
57
Prelude Capital Management
New York
| $10K | +$10.5K | +458 | New |
|
58
Morgan Stanley
New York
| $6K | -$25.4K | -1,104 | -80% |
|
59
Rockefeller Capital Management
New York
| $3K | – | – | – |
|
|
SCM
60
Scopia Capital Management
New York
| – | -$24.1M | -920,282 | Closed |
|
|
MWNA
61
Marshall Wace North America
New York
| – | -$19K | -735 | Closed |
|
|
CCA
62
Catalyst Capital Advisors
Huntington,
New York
| – | -$10K | -400 | Closed |
|
YMAB Hedge Fund Activity: Q2 2019 in Review
59 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2019, worth a combined $251M — up 13% from $222M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new YMAB positions and 4 closed out — a net gain of 16 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $18M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $24.1M sold.
- 59 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2019, up from 45 in Q1 2019.
- Funds reported $251M of Y-mAbs Therapeutics stock for Q2 2019, up 13% quarter-over-quarter.
- 20 funds opened new Y-mAbs Therapeutics positions in Q2 2019 and 4 closed out, a net change of +16 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2019 was BlackRock, an estimated $18M added.
- The largest Y-mAbs Therapeutics seller in Q2 2019 was Scopia Capital Management, an estimated $24.1M sold.
Based on aggregated 13F filings for Q2 2019.